Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Published:2019-06-06 Issue:3 Volume:105 Page:632-639
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

de Swart Louise,Crouch Simon,Hoeks Marlijn,Smith Alex,Langemeijer Saskia,Fenaux Pierre,Symeonidis Argiris,Cermâk Jaroslav,Hellström-Lindberg Eva,Stauder Reinhard,Sanz Guillermo,Mittelman Moshe,Holm Mette Skov,Malcovati Luca,Mądry Krzysztof,Germing Ulrich,Tatic Aurelia,Savic Aleksandar,Almeida Antonio Medina,Gredelj-Simec Njetocka,Guerci-Bresler Agnes,Beyne-Rauzy Odile,Culligan Dominic,Kotsianidis Ioannis,Itzykson Raphael,van Marrewijk Corine,Blijlevens Nicole,Bowen David,de Witte Theo,

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial;The Lancet Haematology;2024-09

2. MDS patient registries - achievements and challenges;Annals of Hematology;2024-08-23

3. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe;Future Oncology;2024-08-14

4. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome;Current Treatment Options in Oncology;2024-05-30

5. Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS‐M) prediction in myelodysplastic syndromes;Journal of Internal Medicine;2024-04-23